3bgb

Publication Abstract from PubMed

Due to the important role that aspartic proteases play in many patho-physiological processes, they have intensively been targeted by modern drug development. However, up to now, only for two family members, renin and HIV protease, approved drugs are available. Inhibitor development, mostly guided by mimicking the natural peptide substrates, resulted in very potent inhibitors for several targets, but the pharmacokinetic properties of these compounds were often not optimal. Herein we report a novel approach for lead structure discovery of non-peptidic aspartic protease inhibitors using easily accessible achiral linear oligoamines as starting point. An initial library comprising 11 inhibitors was developed and screened against six selected aspartic proteases. Several hits could be identified, among them selective as well as rather promiscuous inhibitors. The design concept was confirmed by determination of the crystal structure of two derivatives in complex with the HIV-1 protease, and represents a promising basis for the further inhibitor development.

Achiral oligoamines as versatile tool for the development of aspartic protease inhibitors.,Blum A, Bottcher J, Sammet B, Luksch T, Heine A, Klebe G, Diederich WE Bioorg Med Chem. 2008 Sep 15;16(18):8574-86. Epub 2008 Aug 7. PMID:18760609^[1]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.